Alzheimer Disease Clinical Trials
Alzheimer Disease Trials at a Glance
373 actively recruiting trials for alzheimer disease are listed on ClinicalTrialsFinder across 6 cities in 52 countries. The largest study group is Not Applicable with 152 trials, with the heaviest enrollment activity in Toronto, St Louis, and Paris. Lead sponsors running alzheimer disease studies include Assistance Publique - Hôpitaux de Paris, Indiana University, and Johns Hopkins University.
Browse alzheimer disease trials by phase
Top cities for alzheimer disease trials
Treatments under study
Understanding Alzheimer's Disease Clinical Trials
Lecanemab (Leqembi), approved in 2023 after a landmark phase 3 trial, became the first therapy to demonstrate statistically significant slowing of cognitive decline in early Alzheimer's disease by clearing amyloid plaques from the brain. Donanemab has shown similar promise in clinical trials, reducing the rate of cognitive and functional decline in patients with early symptomatic Alzheimer's. These breakthroughs mark the beginning of a new era, and dozens of clinical trials are now testing therapies that target not only amyloid but also tau tangles, neuroinflammation, and other mechanisms underlying this devastating disease.
Why Consider a Clinical Trial?
Frequently Asked Questions
Common questions about Alzheimer Disease clinical trials
Trials exist for every stage, from people with no symptoms but elevated risk (prevention trials) to those with mild cognitive impairment, early Alzheimer's, and moderate-to-advanced disease. However, the largest number of trials currently focus on the early stages, as treatments may be most effective before extensive brain damage has occurred.
A study partner can be a spouse, adult child, sibling, close friend, or professional caregiver who spends significant time with you each week (usually at least 10 hours). They must be willing to attend study visits, provide observations about your daily functioning, and communicate with the study team. Some trials allow different people to alternate in this role.
Yes. Amyloid PET scans involve a small amount of radioactive tracer that is considered safe by medical standards. The radiation exposure is comparable to a standard CT scan. These scans are an important diagnostic tool and are used to confirm amyloid presence in the brain, which is a requirement for many Alzheimer's trials.
ARIA (amyloid-related imaging abnormalities) are brain swelling or microbleeds detected on MRI scans. They occur in a significant percentage of patients receiving anti-amyloid therapies, are usually mild and temporary, and often produce no symptoms. Trials monitor for ARIA with regular MRI scans, and treatment is paused if significant ARIA is detected.
Yes. Some trials specifically enroll people with genetic risk factors such as APOE4 carriers or those with autosomal dominant Alzheimer's mutations (APP, PSEN1, PSEN2). Genetic testing can help identify trials you qualify for and may provide important information about your personal risk profile. Discuss genetic testing with your doctor or a genetic counselor.
Showing 1–20 of 373 trials